Background: Metastatic bone lesion is a common syndrome of many cancer diseases in an advanced state. The major symptom is severe pain, spinal cord compression, and pathological fracture, associated with an obvious morbidity. 
Background
Bone-seeking radiopharmaceuticals showed promising results in the last decades both for diagnosis and therapy [1] . The mechanism of the therapy effect is the synergy of an enhanced accumulation of osteotropic agents on the metastatic lesion and the energy deposit by particle radiation (β − , inner conversion or α-particles). One of the earliest therapeutic concepts was the administration of 89 SrCl 2 as a calcium mimetic [2] . While 89 Sr showed unfavorable nuclear properties in terms of β-energy and half-life (β max = 1.5 MeV, t 1/2 = 50 days) [3] [1] .
The potential of lanthanide radionuclides for bone targeting was recognized early [4] . Skeletal 177 Lu-images were obtained with the Anger camera already in the 1960s [5] . The γ-photons of 113 keV (6.4 %) and 208 keV (11.4 %) [6] from the 177 Lu decay are suitable for single photon computed tomography (SPECT), whereas today the focus of 177 Lu-compounds is mainly on the therapeutic benefit of the β − -emission. 177 Lu-labelled somatostatin analogues are successfully used in the treatment of neuroendocrine tumors in the peptide receptor radionuclide therapy (PRRT) [7] . The ideal nuclide properties of a half-life of 6.65 days and the maximum β-energy of 0.497 MeV [6] together with the carrier-free production route make 177 Lu an interesting candidate in the treatment of skeletal metastases.
In the early times of radiopharmacy, it was discovered already that the addition of chelating agents alters the biological distribution of lanthanides from primary liver uptake to almost exclusively bone accumulation [5] . "Bone seeking" polycarboxy-polyphosphates like ethylenediamine tetra(methylene phosphonic acid) (EDTMP) showed promising first results [8, 9] . Due to their low kinetic stability with lanthanide ions [10] , a high EDTMP concentration in the blood pool is necessary for a stable complexation in vivo, which consequently creates a high amount of ligand carrier [11] . As opposed to these open-chain chelators, macrocyclic chelators like 1,4,7,10-tetraazacyclododecane N,N′,N″,N″-tetra-acetic acid (DOTA) show a very strong thermodynamic and kinetic stability with lanthanides [12, 13] . Even equimolar metal to DOTA ratios guarantee for complexation and in vivo stability. Initial experiments with phosphonic acid derivatives (DOTP) of DOTA complexed with 177 Lu showed sufficient bone accumulation and low uptake in soft tissue [14] .
An ideal chelator-based positron emission tomography (PET) nuclide is the generator-derived 68 Ga. Phosphonate-based macrocycles for 68 Ga complex formation such as [ 177 Lu outcomes [15, 16] . The first compound, which yielded excellent 68 Ga-PET, was the DOTAbased bisphosphonate BPAMD (for formula, see Chart 1) [17, 18] . It is known that bisphosphonates in general have a high affinity to calcified tissues and a very long biological half-life in the skeleton [19] . [ 68 Ga]BPAMD PET/CT showed uptake values on disseminated bone metastases as high as 18 F-fluoride, sometimes even superior [20] . Recently, the NOTA-derivative [ 68 
Ga]NO2AP
BP was identified to show even improved imaging quality [21] . In a previous work, we investigated the potential of different 68 Ga-labelled DOTA-conjugated bisphosphonates in an animal model as PET imaging agents [22] . The logical step is the following investigation in its potential as therapeutic agents, when labelled with 177 Lu. Nevertheless, we believe that there still are various options to chemically modify those chelate structures in order to maximize uptake on bone metastases and to further reduce soft-tissue accumulation. The current question, discussed in the present paper, is whether analogue macrocyclic bisphosphonate ligands can directly be converted from 68 Ga complexes to 177 Lu analogues, i.e., retaining organ uptake and pharmacology profiles known from Ga(III) structures, or whether an alternative ligand chemistry is needed to match the coordination features of Lu(III).
Currently, several new macrocyclic bisphosphonates are intensely discussed in the literature as candidates for complex formation with 177 Lu and 90 Y and subsequent "bone seeking" parameters, including hydroxy bisphosphonates [23] and phosphinates (Chart 1) [24] . In this paper, the biodistribution and bone accumulation of various macrocyclic bisphosphonates, including two dimeric DOTA and one 1,4,7-triazacyclononane-1,4-diacetic acid (NO2A) compounds (Chart 1), were studied in a healthy rat model. The ligand synthesis, in particular the synthesis of the new dimeric bisphosphonates DO2A(P BP ) 2 and DOTA(M BP ) 2 as well as labelling with 177 Lu and radioanalytics, are reported. All the 177 Lu species were investigated in healthy rats in in vivo small animal SPECT and ex vivo organ distribution (5 min to 1 h p.i.) studies and SUV data or %ID/g data were determined (n = 4) of the interested organs.
Methods

Chemicals
Chemicals and solvents were commercially available in analytical or high-performance liquid chromatography (HPLC) grade and were purchased from Sigma-Aldrich or Merck KGaA.
Analytics
Proton nuclear magnetic resonance ( 1 H-NMR) spectra were recorded on a Bruker 300, and 31 P-NMR were recorded on a Bruker 600. NMR shifts were referenced to internal TMS or externally referenced to 85 % aq. H 3 PO 4 signal. Mass spectra were recorded on an Agilent Technologies 6130 Quadrupole LC/MS spectrometer with ESI as ion source in positive or negative modes. TLC analyses of the ligand and intermediates during their synthesis were carried out with silica on aluminum foil (Merck).
Radio-TLC analyses of labelled compounds were carried out with silica on aluminum foil (Merck) or RP18 on alumina and a Canberra Packard Instant Imager. Radio-HPLC was performed on a Hewlett Packard Series 1100 with a Raytest (Radeberg, Germany) Ramona radiodetector. Radioactivity of samples was measured with an Aktivimeter Isomed 2010, MED (Nuklear-Medizintechnik Dresden GmbH).
Radionuclides
No-carrier-added (n.c.a.) 177 Lu was produced via the 176 Yb-based neutron capture pathway provided by ITG (Garching, Germany) as LuCl 3 in 0.04 M HCl [25] . 
The protected compound (2) (308.5 mg, 0.29 mmol) was dissolved in dry dichloromethane, and trimethylsilylbromide (20 eq., 6 mmol, 920 mg) was added at room temperature under argon atmosphere. The reaction mixture was stirred overnight, and volatiles were removed under reduced pressure. The resulting red oil was dissolved in methanol and stirred for 5 h until the solvent was removed. The residue was kept under high vacuum to remove volatiles until no change in weight was observed. A subsequent 2:1 mixture of TFA/DCM was added and the mixture was stirred overnight under argon atmosphere. After removing the solvents under reduced pressure, the crude compound was purified two times by recrystallization from boiling water. The precipitating white solid was filtered, washed with ethanol, and dried in vacuum with a yield of 140 mg (64 %).
J PH = 18.22 Hz). 
DO2A(P BP ) 2 (6)
The protected bisphosphonate (5) (625 mg, 0.52 mmol) was dissolved in 50 mL 6 M aqueous HCl and kept at a temperature of 100°C for 24 h. The solvent was evaporated under reduced pressure, and the excess of HCl was removed by repetitive co-evaporation from deionized water. The crude product was passed over a strong cation exchanger (Dowex 50, H + -form), and the aqueous solution was dried by lyophilization. The white solid was further purified by recrystallization from boiling water. Precipitation was initiated by adding small volumes of ethanol. The white solid (337 mg, 79 %) was filtered, washed with ethanol, and dried in vacuum. were determined by radio-HPLC (Zorbax 300SB-C18, 9.4 × 250 mm 5 μ, solvent: 100 mM tetraethylammonium phosphate pH = 2.24, 1 mL/min isocratic flow) and were cross-checked by two radio-TLC methods (silica, solvent: 0.1 M citrate buffer pH 4 and RP18 on alumina, solvent: 100 mM tetraethylammonium phosphate pH = 2.24 + 20 % ACN).
Animal studies
The experiments were realized corresponding to the German animal welfare regulations and institutional guidelines and with the permission of the local animal research committee at the Landesdirektion, Dresden. All experimental procedures are following the guidelines of the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (ETS No. 123). Male Wistar rats weighing 157.69 ± 17.10 g (mean ± SD, N = 35) were purchased from Unilever (HsdCpb:WU, Harlan Winkelmann, Borchen, Germany). Anesthetization was initiated and maintained by desflurane, and animals were put in the supine position and placed on a heating pad to maintain body temperature. A needle catheter was used for administration of the tracers in the tail vein. A second catheter was introduced into the right femoral artery for the extraction of blood samples for metabolite analysis, which was routinely done during SPECT/CT measurements.
Ex vivo biodistribution
The male Wistar rats received a short-term anesthetization by desflurane inhalation. Mean activities of 2.36 ± 0.27 MBq/kg of the 177 Lu-labelled tracers in isotonic saline were injected in a volume of 0. 5 177 Lu activity was determined with a Wallac WIZARD automatic gamma counter (PerkinElmer, Germany) and decay corrected. The distribution data are expressed in %ID or are normalized to the BW as standard uptake value (SUV), which was calculated with the formula: SUV = (activity per g tissue)/(injected activity) × BW. The skeleton weight was calculated using the following: skeleton weight = 9.66 + 0.0355 × BW, and the total activities associated with the skeleton were calculated by using the activity concentration in the femur and the total skeleton weight [29] .
Metabolite analysis and in vivo stability
Arterial blood plasma samples were taken during SPECT/ CT examinations after 1, 3, 5, 10, 20, 2 was analyzed. Plasma was separated by centrifugation (3 min, 11,000×g) followed by precipitation of the plasma proteins with ice-cold methanol (1.5 parts per 1 part plasma) and centrifugation (3 min, 11,000×g). The supernatants were analyzed by radio-TLC and HPLC using the abovementioned methods for quality control. Additionally, urine samples were treated in the same way prior radio-TLC and radio-HPLC analysis.
SPECT/CT
Tracer accumulation in vivo was monitored with a NanoScan ® SPECT (Mediso Medical Imaging Systems, Budapest, Hungary) scanner. CT images were obtained with a NanoScan ® PET/CT (Mediso Medical Imaging, Budapest Hungary) scanner. Rats were prone and head-first positioned. The animals were anesthetized by 5 % desflurane inhalation.
Statistical analysis
The statistical analysis was performed by using GraphPad Prism (V5.02 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com). Data are expressed as an average ± standard deviation (S.D.). Twotailed Student's t test or ANOVA was usually done to compare groups of data.
Results
Synthesis
The pendant arms (1) and (4) were prepared as described in literature procedures (see experimental part) in good yields. Alkylation of DO2A was done by a nucleophilic substitution (2) or by a mannich-like reaction (5), followed by a two-step cleavage (3) of the protection groups, by using trimethylsilyl bromide as a mild and efficient deesterification agent of ethyl-protected bisphosphonates and trifluoroacetic acid for the tert.-butylesters of the carboxylic acid arms. Aqueous HCl (6 M) was used to de-protect the phosphinate compound (6) (Schemes 1 and 2) . The final dimeric bisphosphonates DOTA(M BP ) 2 (3) and DO2A(P BP ) 2 (6) were obtained in moderate yields after resin and recrystallization purification.
Radiolabelling with n.c.a. 177 Lu and quality control
The DOTA-, DO2A-, and NO2A-conjugated bisphosphonates were successfully labelled with n.c.a.
177
Lu(III). Yields and purities were controlled by radio-TLC and HPLC ( Fig. 1 Lu ]citrate was found in the harderian glands with a value of 9.62 ± 5.62, which is more than the doubled uptake value compared to the femur after 60 min p.i. in contrast to the tested bisphosphonates, which showed almost no uptake in the harderian glands. The data showing that the bone accumulation is Data are expressed in SUV. Each value represents the mean (S.D.) for five animals. As an exception are the data in three decimal places to show also the very low values n.d. data not determined completed after 60 min and is stable for 8 days. Figure 2 summerizes the bone accumulation of the investigated complexes. Figure 3 represents the activity concentration in the blood over time.
The "bone to soft tissue" ratios are presented in Tables 4,  5 , and 6. The best bone-to-muscle ratio was observed for [ 2 increased to 64.5 ± 1.5 %ID but showed at the same time the minimal target to soft-tissue ratio.
Metabolite analysis and in vivo stability
Radio-HPLC and TLC analysis of blood samples showed no evidence of any metabolization of the compounds [ 
SPECT/CT molecular imaging in vivo
Images obtained from SPECT showed that the therapeutic 177 Lu-labelled bisphosphonates exclusively accumulated in the skeleton with a high target-tobackground ratio, cf. Figs. 4 and 5. No considerable fractions of 177 Lu activity were found in other organs after 60 min, which is consistent to the data gathered from the ex vivo biodistribution. An obvious amount of activity was present in the growth plate as well as in other articulations.
Discussion
The DOTA-based monomeric bisphosphonates BPAMD, BPAPD, and BPPED have been successfully radiolabeled with the therapeutic β − -emitter 177 Lu(III) in excellent yields over 98 % as well as the NO2A-based bisphosphonate NO2AP BP and the dimeric compounds DOTA(M BP ) 2 and DO2A(P BP ) 2 . All tracers tested showed a distinguished high accumulation on the bone surface, eminently in the epiphyseal plate. We suppose that this particular uptake in the epiphyseal areas may serve as an analogy to the tracer's behavior on bone metastases. High uptakes were observed for the dimeric compound [
177 Lu]DOTA(M BP ) 2 (SUV femur = 5.41 ± 0.41). All bisphosphonates underwent a renal body clearance, and the blood elimination was very fast especially for the monomeric compounds. No brain or notable liver uptake was observed. The compounds were found to be complete intact in the urine and blood. The characteristic accumulation specific in the growth plate of the skeleton shows that the compound uptake profile is subject to the bone turnover. For that reason, the described compounds in this manuscript should be well suited for a targeted 177 Lu therapy to osteoblastic bone metastases, where they should preferably accumulate. An important factor for a therapeutic application is the target-to-background ratio (TBR) and a fast excretion of non-target bond activity. A good TBR and a fast blood and body clearance reduces the radiation dose of the nontargeted tissue and thus will reduce toxic side effects and enhances the therapeutic efficiency and tolerance.
Although 
